drugset / Trial / NCT03646058

Add-on Buprenorphine at Analgesic Doses for the Treatment of Severe Suicidal Ideas During a Major Depressive Episode

NCT03646058

Phase 3 Recruiting 180 enrolled Nîmes University Hospital
RandomizedParallel-groupDouble-blindTreatment

Summary

This study aims at investigating if adjunctive buprenorphine at low dose to treatment as usual is effective in reducing severe suicidal ideas in major depressive episode, and at determining the most effective dose.

Timeline

Start
2021-10-10
Primary completion
2026-10
Completion
2027-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Buprenorphine Other / unclassified 0.4 mg Other
Subject Buprenorphine Other / unclassified 0.8 mg Other